Skip to Content

Velaglucerase alfa use while Breastfeeding

Drugs containing Velaglucerase alfa: VPRIV

Medically reviewed by Drugs.com. Last updated on April 24, 2021.

Velaglucerase alfa Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the clinical use of velaglucerase during breastfeeding. Velalglucerase is a synthetic form of beta-glucocerebrosidase, which is a normal component of human milk, but has an identical amino acid sequence to the normal enzyme. Studies with other forms of the enzyme have found very low levels of the enzyme in breastmilk. Absorption by the infant is unlikely because it is probably destroyed in the infant's gastrointestinal tract.[1,2] A limited amount of data support the safety of breastfeeding with alglucerase (the placenta-derived form of the enzyme) and imiglucerase (another biosynthetic form of the enzyme). An international panel of clinicians from 9 centers that treat Gaucher's disease reported that, breastfeeding complications were less frequent in mothers who were treated with alglucerase or imiglucerase postpartum than in untreated mothers with Gaucher's disease. Consider limiting the duration of breastfeeding to about 6 months to avoid excessive bone loss in the nursing mother.[2,3]

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Alglucerase, Imiglucerase, Taliglucerase Alfa

References

1.
Belmatoug N. Considerations for pregnant patients with Gaucher disease: challenges for the patient and physician. Clin Ther. 2009;31 Suppl. 3:S192–3. [CrossRef]
2.
Zimran A, Morris E, Mengel E, et al. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause). Blood Cells Molec Dis. 2009;43:264–88. [PubMed: 19502088]
3.
Granovsky-Grisaru S, Belmatoug N, vom Dahl S, et al. The management of pregnancy in Gaucher disease. Eur J Obstet Gynecol Reprod Biol. 2011;156:3–8. [PubMed: 21269752]

Substance Identification

Substance Name

Velaglucerase alfa

CAS Registry Number

884604-91-5

Drug Class

Breast Feeding

Lactation

Enzymes

Enzyme Replacement Therapy

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.